Regeneron

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. 

CEO
Leonard S. Schleifer
CEOLeonard S. Schleifer
Employees
15,410
Employees15,410
Headquarters
Tarrytown, New York
HeadquartersTarrytown, New York
Founded
1988
Founded1988
Employees
15,410
Employees15,410

REGN Key Statistics

Market cap
82.41B
Market cap82.41B
Price-Earnings ratio
18.86
Price-Earnings ratio18.86
Dividend yield
0.45%
Dividend yield0.45%
Average volume
786.88K
Average volume786.88K
High today
$780.88
High today$780.88
Low today
$770.00
Low today$770.00
Open price
$775.00
Open price$775.00
Volume
591.45K
Volume591.45K
52 Week high
$821.11
52 Week high$821.11
52 Week low
$476.49
52 Week low$476.49

Stock Snapshot

Regeneron(REGN) stock is priced at $779.67, giving the company a market capitalization of 82.41B. It carries a P/E multiple of 18.86 and pays a dividend yield of 45.0%.

During the trading session on 2026-02-20, Regeneron(REGN) shares reached a daily high of $780.88 and a low of $770.00. At a current price of $779.67, the stock is +1.3% higher than the low and still -0.2% under the high.

Trading volume for Regeneron(REGN) stock has reached 591.45K, versus its average volume of 786.88K.

The stock's 52-week range extends from a low of $476.49 to a high of $821.11.

The stock's 52-week range extends from a low of $476.49 to a high of $821.11.

REGN News

TipRanks 1d
Regeneron announces FDA accepted Priority Review for BLA for garetosmab

Regeneron (REGN) Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has accepted for Priority Review the Biologics License Application,...

Nasdaq 2d
Ex-Dividend Reminder: ONE Gas, AstraZeneca and Regeneron Pharmaceuticals

Looking at the universe of stocks we cover at Dividend Channel, on 2/20/26, ONE Gas, Inc. (Symbol: OGS), AstraZeneca plc (Symbol: AZN), and Regeneron Pharmaceut...

Ex-Dividend Reminder: ONE Gas, AstraZeneca and Regeneron Pharmaceuticals
Simply Wall St 3d
Can Regeneron Turn Niche Allergen Antibodies Into a Broader Immunology Growth Engine?

In February 2026, Regeneron Pharmaceuticals announced that 36 abstracts from its immunology and inflammation portfolio were presented at the AAAAI Annual Meetin...

Can Regeneron Turn Niche Allergen Antibodies Into a Broader Immunology Growth Engine?

Analyst ratings

72%

of 29 ratings
Buy
72.4%
Hold
27.6%
Sell
0%

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.